<DOC>
	<DOCNO>NCT02769767</DOCNO>
	<brief_summary>HLA-DRB1 * Gene gene involve inflammation immunity ( IL-7R , GPC5 , CTSS ) link risk MS response treatment immunomodulators . This research aim estimate risk confers variation sequence gene .</brief_summary>
	<brief_title>Polymorphisms Interleukins , Glypican , Human Leukocyte Antigen Genes Treatment Response Multiple Sclerosis .</brief_title>
	<detailed_description>Genes HLA-DRB1 * gene involve inflammation immunity link risk MS response treatment immunomodulators . The HLA-DRB1 * gene associate risk response treatment MS multiple study ; however , gene controversial . This research aim estimate risk MS confers variation sequence IL-7R , GPC5 , CTSS , HLA-DRB1 gene . Furthermore , seek determine whether gene variant ( polymorphism ) associate treatment response immunomodulators . Subjects MS healthy subject take assess risk MS . Besides investigator obtain medical history relapse assess response treatment accordance Expanded Disability Status Scale ( EDSS ) relapse .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Inclusion Criteria Cases : Subjects multiple sclerosis 18 EDSS less 5 Signed inform consent Inclusion Criteria Controls : Healthy subject 18 Signed inform consent Exclusion Criteria Cases : Mental retardation Withdrawal consent No immunomodulatory treatment Exclusion Criteria Controls : Mental retardation Withdrawal consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>